Growth In ANDA Submissions Is Leveling Off, OGD Director Says
This article was originally published in The Pink Sheet Daily
While still growing and setting records, change in pace of submissions could give FDA "breather" to work on backlog.
You may also be interested in...
GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.
America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.